At the news
? NEUTRALIMPACT 3/10 6-K filed Sep 14, 2026 at 08:05 ET
Evaxion announced it is applying its AI-Immunology platform to autoimmune diseases, testing two novel treatment concepts (tolerogenic vaccine and autoantibody binder). Initial experimental data is expected at PEGS Europe in November 2026. This is a preclinical pipeline expansion with no financial data or near-term catalyst, representing a modest strategic update for a clinical-stage company.
- Evaxion is applying its AI-Immunology platform to autoimmune diseases, expanding beyond cancer and infectious diseases.
- Two novel concepts are being tested: a tolerogenic vaccine and an autoantibody binder.
- Initial experimental data will be presented at PEGS Europe in Lisbon on November 18, 2026.
- No financial terms, partnership agreements, or clinical trial data were disclosed in the filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access